GLycaemic Outcomes With Whey Protein in ageING

NCT ID: NCT07285811

Last Updated: 2025-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-31

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this placebo-controlled, partial crossover design study is to identify the impact of consuming whey protein before meals on free-living glucose control in older adults living with type 2 diabetes.

The primary specific objective is to determine the effect of a thrice daily whey protein pre-meal supplementation at two doses, on glucose excursions over a 7-day free-living period in adults aged 75-90 years of age, living with type 2 diabetes, compared with a non-protein placebo.

Participants will consume the whey protein and placebo for 7 days each, before each meal. All participants will consume the placebo and one of two doses of whey protein, in a randomised order.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Within the study, the researchers will look at the effect of supplemental whey protein at moderate and low doses in comparison to each other and a protein-free placebo on glycaemic control in older adults aged between 75-90 years of age, living with type 2 diabetes.

Glycaemic control (glucose excursions) will be monitored under free-living conditions over a 7-day period using continuous glucose monitors (CGMs). Participants will be randomised to consume one of the two whey protein doses as well as the protein-free placebo on a separate 7-day period. The order of consuming whey protein or the protein-free placebo will be randomised and counterbalanced. This study is under the evidence that in younger people living with type 2 diabetes, a moderate dose of whey protein improves glucose time in range and lessens extreme postprandial glucose excursions.

Participants will be free to consume their typical diet over this period, where the researchers will provide a diet diary for participants to enter in all foods and drinks they consume over this time period, as well as document the ingestion of the supplement before each main meal.

During an acute feeding period on the first ingestion of each supplement (start of each 7-day phase), the researchers will evaluate rates of gastric emptying, glucose and insulin concentrations and hormonal appetite markers through blood draws, as well as perceived appetite responses through visual analogue scales. This will be in a research kitchen where participants will consume the supplement and a controlled mixed meal afterwards to monitor excursions in appetite response and glycemia. The researchers will also investigate the impact of pre-meal protein feeding on renal markers following each 7-day phase via urine collection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Placebo-controlled partial crossover
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pre-meal low dose whey protein

Low whey protein dose administration before meals

Group Type ACTIVE_COMPARATOR

Glycaemic control with whey protein

Intervention Type DIETARY_SUPPLEMENT

Comparing pre-meal supplementation of whey protein to protein-free placebo.

Glycaemic control with different doses of whey protein

Intervention Type DIETARY_SUPPLEMENT

Comparing pre-meal supplementation of moderate whey protein to a low dose of whey protein.

pre-meal moderate dose whey protein

Moderate whey protein dose administration before meals

Group Type ACTIVE_COMPARATOR

Glycaemic control with whey protein

Intervention Type DIETARY_SUPPLEMENT

Comparing pre-meal supplementation of whey protein to protein-free placebo.

Glycaemic control with different doses of whey protein

Intervention Type DIETARY_SUPPLEMENT

Comparing pre-meal supplementation of moderate whey protein to a low dose of whey protein.

pre-meal protein-free placebo

protein-free placebo administration before meals

Group Type PLACEBO_COMPARATOR

Glycaemic control with whey protein

Intervention Type DIETARY_SUPPLEMENT

Comparing pre-meal supplementation of whey protein to protein-free placebo.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glycaemic control with whey protein

Comparing pre-meal supplementation of whey protein to protein-free placebo.

Intervention Type DIETARY_SUPPLEMENT

Glycaemic control with different doses of whey protein

Comparing pre-meal supplementation of moderate whey protein to a low dose of whey protein.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* \<75 years old and over 90 years of age
* Currently on fast-acting insulin therapy (i.e., Humalog)
* Confirmed uncontrolled diabetes (HbA1C \>10% or 85mmol/mol).
* Currently on GLP-1 therapy
* Habitual smoker or vaper
* Veganism
* Lactose or dairy intolerance
* Coeliac or gluten intolerance
* History of gastrointestinal disease
* Experienced a hyperglycaemic or hypoglycaemic event requiring treatment in the past 12 months
* Recent Ischemic stroke (\<3 months).
* Use of anticoagulants (e.g. warfarin, rivaroxaban)
* Considered unwilling or unable to comply with the study protocol requirements by the research team
Minimum Eligible Age

75 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Newcastle University

OTHER

Sponsor Role collaborator

University of Birmingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Leigh Breen, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Birmingham and University of Leciester

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham

Birmingham, West Midlands, United Kingdom

Site Status ENROLLING_BY_INVITATION

Heartlands Hospital

Birmingham, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Leigh Breen, PhD

Role: CONTACT

(0)1214144109 ext. +44

Marie Korzepa, PhD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Srikanth Bellary, MD

Role: primary

4240234 ext. 0121

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RG_24-052

Identifier Type: -

Identifier Source: org_study_id